Oportuzumab (Anti-EpCAM / TROP1 / CD326)

Oportuzumab (Anti-EpCAM / TROP1 / CD326) is a humanized monoclonal antibody targeting EpCAM. It exhibits potential in treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. MW :145.4 KD.

• Supplier: Selleck Chemicals
• Product #: A2992
• Sku #: A2992-1mg*5